Chemomab Therapeutics Director Alan Moses Files Form 3 Disclosing Stock Option Holdings

This Form 3 filing discloses the initial statement of beneficial ownership of securities by Alan Moses, a director of Chemomab Therapeutics Ltd. (CMMB). The filing reveals Moses holds six separate stock option grants to purchase American Depositary Shares, with exercise prices ranging from $2.14 to $109.04 per share. The options were granted between April 2021 and March 2026, with expiration dates extending through 2036. All options are reported as fully vested and exercisable as of the filing date. The filing was submitted under temporary relief provisions for foreign private issuers, as it was filed after March 18, 2026 but before April 20, 2026. The total underlying ADS represented by these options amounts to 17,903 shares, indicating significant equity-based compensation for the director.